Skip to content
All Podcasts – Lifestyle
Author:
Sunshine Biopharma Inc.
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
August 4, 2026
Health Canada Approves Sunshine Biopharma’s Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
July 28, 2026
Galway Metals Commences Preliminary Economic Assessment at Clarence Stream Gold Project
July 23, 2026
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
July 20, 2026
Galway Metals Reports Updated Clarence Stream Mineral Resource Estimate
July 13, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
June 25, 2026
Galway Metals Reports 5.0 g/t Gold over 10.85 Metres at North Deposit and Continues to Intersect Gold in Northern Extension
June 10, 2026
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
June 1, 2026
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
May 29, 2026
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
May 28, 2026
1
2
Next Page
→